Core Viewpoint - The company reported a total product revenue exceeding 5.2 billion yuan in the first half of 2025, representing a year-on-year growth of 35% [1][3]. Revenue Growth - In Q2 2025, the total product revenue surpassed 2.7 billion yuan, showing a year-on-year increase of 30% and a quarter-on-quarter growth of 12.5% [1][3]. - The growth was primarily driven by the oncology segment and the comprehensive product line, with stable growth from main products and an increasing revenue share from new products [3][5]. Profitability Status - The company did not disclose whether it achieved profitability, nor did it provide information on Non-IFRS profit or Non-IFRS EBITDA [3][5]. - In 2024, the Non-IFRS profit and Non-IFRS EBITDA were reported at 332 million yuan and 412 million yuan, respectively, both turning positive for the first time, although the net profit remained negative [5][8]. Product Pipeline - The product pipeline is divided into oncology and comprehensive categories, with oncology being the main revenue source as of 2024 [8][10]. - The company launched five new approved drugs in 2024, including three targeted therapies for lung cancer and the world's first non-covalent BTK inhibitor for blood cancers [9][10]. Future Growth Potential - The company plans to raise 4.3 billion HKD for research and development, focusing on key pipelines like IBI-363 and IBI-343, which have received breakthrough therapy designations [10][15]. - The comprehensive pipeline, particularly the recently approved weight management drug, is crucial for the company's performance in the next two to three years [10][15]. Market Competition - The domestic GLP-1 drug market is becoming increasingly competitive, with 21 GLP-1 drugs already available for various indications as of July 2025 [11][14]. - The CFO indicated that the company will leverage both traditional and online retail channels for the commercialization of its products [14][15]. Long-term Goals - The company aims to achieve a product revenue target of 20 billion yuan by 2027 and plans to have five pipelines enter global multi-center phase III clinical trials by 2030 [15].

Summary of Innovent Biologics Conference Call Company Overview - **Company**: Innovent Biologics (1801.HK) - **Industry**: Biopharmaceuticals, focusing on immuno-oncology and metabolic diseases Key Financial Performance - **2Q25 Product Revenue**: Exceeded Rmb2.7 billion, representing a **35% year-over-year increase** and a **13% quarter-over-quarter increase** from Rmb2.4 billion in 1Q25 [1] - **Tyvyt Sales**: Reported at US$137 million in 2Q25, a **19% year-over-year increase**, but largely flat compared to previous quarters [1] - **New Product Launches**: Five new products launched in 2025, contributing to a **186% year-over-year increase** in sales from the new product portfolio, excluding Tyvyt and biosimilars [1] Market Position and Strategy - **Mazdutide**: Recently approved and launched, positioned favorably in the obesity market, especially amid NOVO's destocking in China [2] - **Pricing Advantage**: Mazdutide priced at approximately Rmb2,920 per month, offering a discount compared to competitors like Zepbound [2] - **Sales Growth Drivers**: Continued momentum expected in 1H25, driven by strong uptake in tafolecimab post NRDL inclusion and the anticipated sales uptake of mazdutide [1][2] Competitive Landscape - **NOVO's Ozempic Sales**: Experienced a **37% year-over-year decline** in 2Q25 due to destocking, creating an opportunity for mazdutide to capture market share [2] - **Market Dynamics**: The obesity market in China is seen as expanding due to limited competition and NOVO's passive strategy, which benefits Innovent's proactive promotion of mazdutide [2] Financial Projections and Valuation - **2025 Revenue Forecast**: Full-year product sales projected at Rmb11.7 billion, a **42% year-over-year increase** [1] - **Target Price**: Updated DCF-based 12-month target price set at HK$98.23, reflecting a **7.5% upside** from the current price of HK$91.40 [7][15] - **Earnings Estimates**: Adjusted EPS estimates for 2025-2027 reflect slight downward revisions due to near-term sales growth adjustments [7] Risks and Considerations - **Key Risks**: 1. Intensifying competition in the PD-1/L1 market in China [7][13] 2. Uncertain approval timelines for key candidates [7][13] 3. Potential restrictions on off-label use due to safety issues [7][13] 4. Risks associated with R&D project failures [7][13] Conclusion - Innovent Biologics is positioned to leverage its strong product pipeline and market dynamics to drive growth, particularly with the launch of mazdutide. The company is viewed as undervalued relative to its potential, with a favorable outlook for continued revenue growth in the coming years.

Core Insights - The company reported total product revenue exceeding RMB 5.2 billion for the first half of the year, maintaining a strong growth rate of over 35% year-on-year [1] - In Q2 2025, total product revenue surpassed RMB 2.7 billion, with a year-on-year growth of over 30%, driven by both oncology and comprehensive pipelines [1] Oncology and Comprehensive Pipeline - The oncology treatment sector continues to show strong performance with leading brands and product combinations, while new product revenue contributions are steadily increasing [1] - The comprehensive product line is gradually releasing its potential, with new drivers of growth coming from products like Xinbile® (Tolebrutinib injection) and Xinbimin® (Tremelimumab N01 injection), which are making progress in marketing and channel access [1] - The approval of the world's first glucagon/GLP-1 dual receptor agonist, Xinermai® (Masitide injection), for weight loss indications by the National Medical Products Administration of China adds a significant product to the company's comprehensive pipeline [1] Product Approvals and Clinical Research - The company has successfully obtained approvals for 16 products, with 2 additional products under review by the National Medical Products Administration of China [1] - Four new drug molecules are currently in Phase 3 or pivotal clinical studies, and approximately 15 new drug candidates have entered clinical research [1]

Core Insights - The company reported total product revenue exceeding RMB 5.2 billion for the first half of the year, reflecting a strong growth of over 35% year-on-year [1] - In Q2 2025, total product revenue surpassed RMB 2.7 billion, with a year-on-year growth of over 30%, driven by both oncology and comprehensive pipelines [1] Oncology and Comprehensive Pipeline - The oncology treatment sector continues to show strong performance with leading brands and product combinations, while new product revenue contributions are on the rise [1] - The comprehensive product line is gradually releasing its potential, with new growth drivers from products like Xinbile® (Tolebrutinib injection) and Xinbimin® (Tremelimumab N01 injection), which are making progress in marketing and channel access [1] - The approval of the world's first dual receptor agonist for glucagon/GLP-1, Xinermai® (Masitide injection), for weight loss indication by the National Medical Products Administration of China adds a significant product to the company's comprehensive pipeline [1] Product Approvals and Clinical Research - The company has successfully obtained approvals for 16 products, with 2 additional products under review by the National Medical Products Administration of China [1] - Four new drug molecules are currently in Phase 3 or pivotal clinical studies, and approximately 15 new drug candidates have entered clinical research [1]

Core Insights - The company, Sinopharm (01801.HK), reported that its total product revenue exceeded 5.2 billion yuan in the first half of 2025, representing a year-on-year growth of over 35% [1] - In the second quarter, the total product revenue surpassed 2.7 billion yuan, with a year-on-year increase of over 30% [1] - The sustained growth in the second quarter is attributed to the dual drivers of oncology and comprehensive pipeline development [1]

（文章来源：第一财经） 信达生物在港交所发布公告，上半年总产品收入超52亿元，同比增超35%；第二季度产品收入超27亿 元，同比增长超30%。 ...

Group 1 - The company reported total product revenue exceeding RMB 5.2 billion in the first half of 2025, maintaining a strong growth of over 35% year-on-year [1] - In Q2 2025, total product revenue surpassed RMB 2.7 billion, with a year-on-year growth of over 30%, driven by both oncology and comprehensive product lines [1] - The growth in the oncology treatment sector is attributed to a strong brand and product portfolio, with major products showing excellent growth and new product contributions increasing [1] Group 2 - The company is focused on sustainable growth and global innovation, with a rich pipeline in oncology and comprehensive product lines (cardiovascular and metabolic, autoimmune, and ophthalmology) [2] - As of now, the company has obtained approval for 16 products, with 2 under review by the National Medical Products Administration of China, and 4 new drug molecules in Phase 3 or pivotal clinical studies [2] - The year 2025 marks an important period for the company as it aims to become an internationally leading biopharmaceutical company [2]

Core Insights - The company reported total product revenue exceeding RMB 5.2 billion in the first half of 2025, maintaining a strong growth rate of over 35% year-on-year [1] - In Q2 2025, total product revenue surpassed RMB 2.7 billion, with a year-on-year growth of over 30% [1] Group 1: Revenue Growth - The continuous growth in revenue is driven by both oncology and comprehensive product lines [1] - Key products in the oncology treatment field have shown excellent growth, with new product contributions increasing [1] - The comprehensive product line is gradually releasing its potential, contributing new growth drivers [1] Group 2: Product Pipeline and Approvals - The company has achieved 16 product approvals, with 2 products under review by the National Medical Products Administration of China [2] - Four new drug molecules are in Phase 3 or critical clinical studies, and approximately 15 new drug candidates have entered clinical research [2] - The approval of the dual receptor agonist drug for weight loss, 信尔美® (玛仕度肽注射液), adds an important product to the comprehensive product line [1] Group 3: Strategic Vision - The company is focused on sustainable growth and global innovation, with a strong pipeline in oncology and comprehensive product lines [2] - 2025 is a significant year for the company as it aims to enter a new phase of dual-driven growth and global innovation [2] - The vision is to become an internationally leading biopharmaceutical company [2]

Core Insights - The company reported total product revenue exceeding RMB 5.2 billion in the first half of 2025, maintaining a strong growth rate of over 35% year-on-year, with Q2 revenue surpassing RMB 2.7 billion, reflecting a growth of over 30% [1] - The sustained growth is driven by a dual engine of oncology and comprehensive product lines, with strong performance from leading brands and new product contributions [1] - The approval of the weight loss indication for the world's first GCG/GLP-1 dual receptor agonist, Senlima® (Masitide Injection), by the National Medical Products Administration of China marks a significant addition to the company's comprehensive product line [1] Company Strategy - The company is committed to sustainable growth and global innovation, focusing on oncology and comprehensive product lines, including cardiovascular, metabolic, autoimmune, and ophthalmology [2] - As of now, the company has obtained approvals for 16 products, with 2 under review by the National Medical Products Administration of China, and 4 new drug molecules in Phase 3 or pivotal clinical studies, along with approximately 15 new drug candidates in clinical research [2] - The year 2025 is pivotal for the company as it enters a new phase of dual-driven growth and global innovation, aiming to become a world-class biopharmaceutical company [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） 本公告所載財務資料乃根據本集團內部管理記錄編製，未經外聘核數師審核或審 閱，因此，有關資料僅供投資者參考。由於收集及編製有關資料過程中出現的各 種不確定性，有關資料可能有別於本公司將刊發經審核或未經審核綜合財務報表 所披露的資料（包括但不限於年度或半年度公佈的資料）。本公告並不構成亦不應 詮釋為購買或出售本集團任何證券或金融工具的要約或招攬。 （股份代號：1801） 內幕消息公告－2025年第二季度產品收入的最新消息 本公告由信達生物製藥（「本公司」，連同其附屬公司統稱「本集團」）根據香港聯合 交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法例第571章證券及 期貨條例第XIVA部作出。 於2025年上半年，本公司共取得總產品收入超人民幣52億元，同比保持35%以上 的強勁增長；其中2025年第二季度總產品收入超過人民幣27億元，同比增長超過 30%。該 ...